Monthly Income Funds From Cohen & Steers (June Update)

Cohen & Steers, Inc. offers institutional-quality closed-end funds focused on real assets and alternative income, with a recent real estate sell-off creating attractive entry points. Fund sectors include real estate, preferred securities, infrastructure, utilities, and fixed income. C&S's expertise in alternatives, active management, and reliable monthly distributions make their CEFs excellent tools for diversification and steady income.

Seeking Alpha • Jun 24, 2026

MapLight Therapeutics Announces Changes to Board of Directors

SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders, today announced the appointment of Martin Babler and Troy Cox to its Board of Directors following their election at the Company's Annual Meeting of Stockholders on June 23, 2026. Mr. Babler and Mr. Cox succeed Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., who did not stand for re-election and have concluded their service on the Board. Mr. Babler has been appointed as a member of the Audit Committee, and Mr. Cox has been appointed Chair of the Nominating and Corporate Governance Committee.

GlobeNewsWire • Jun 24, 2026

Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th

CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD.

GlobeNewsWire • Jun 23, 2026

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervous system (CNS).

PRNewsWire • Jun 22, 2026

Cohen & Steers Closed-End Funds Declare Distributions for July, August and September 2026

NEW YORK, June 22, 2026 /PRNewswire/ -- The Board of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for July, August and September 2026, as summarized in the charts below: Ticker Fund Name Monthly Dividend FOF Cohen & Steers Closed-End Opportunity Fund, Inc. $0.087 LDP Cohen & Steers Limited Duration Preferred and Income Fund, Inc. $0.131 PSF Cohen & Steers Select Preferred and Income Fund, Inc. $0.126 PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund $0.134 RFI Cohen & Steers Total Return Realty Fund, Inc. $0.080 RLTY Cohen & Steers Real Estate Opportunities and Income Fund $0.110 RNP Cohen & Steers REIT and Preferred and Income Fund, Inc. $0.136 UTF Cohen & Steers Infrastructure Fund, Inc. $0.165 Distributions will be made on the following schedule: Month Ex-Dividend/ Record Date Payable Date July  Jul. 14, 2026  Jul. 31, 2026 August Aug. 11, 2026 Aug. 31, 2026 September Sept. 8, 2026 Sept.

PRNewsWire • Jun 22, 2026

Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining patients, caregivers, and advocacy organizations in raising awareness of brain health and the impact of Alzheimer's disease during Alzheimer's & Brain Awareness Month. “Nearly everyone knows brain health is important, but many people aren't sure what steps to take to protect it,” said Wendy Vizek, Senior Vice President, Community Engagement and Field Operations at the Alzheimer's Association.

GlobeNewsWire • Jun 18, 2026

Latus Bio Appoints Bethany Mancilla as Chief Business Officer

PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company engineering gene therapies at scale, today announced the appointment of Bethany Mancilla as Chief Business Officer. Ms. Mancilla brings a breadth of corporate development experience across large and small biotechnology companies, including an extensive history of transactions in gene therapy and central nervous system (CNS) disorders. “Bethany joins Latus at a defining moment as we advance LTS-201 toward th.

Business Wire • Jun 16, 2026

Cohen & Steers Completes Conversion of Future of Energy Mutual Fund to Active ETF

NEW YORK, June 15, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced it has completed the conversion the Cohen & Steers Future of Energy Fund (MLOIX) into a new, actively managed exchanged-traded fund (ETF), the Cohen & Steers Future of Energy Active ETF (CSEN). CSEN, listed today on Nasdaq with $189 million in assets, expands Cohen & Steers' actively managed real assets and alternative income ETF platform to more than $1 billion in assets under management[1].

PRNewsWire • Jun 15, 2026

Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2026

NEW YORK, June 8, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $99.5 billion as of May 31, 2026, a decrease of $645 million from assets under management of $100.1 billion at April 30, 2026. The decrease was due to market depreciation of $592 million and distributions of $154 million, partially offset by net inflows of $101 million.

PRNewsWire • Jun 8, 2026

Cohen & Steers Quality Income Realty Fund, Inc. Announces Terms of Transferable Rights Offering

NEW YORK, June 8, 2026 /PRNewswire/ -- Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") announced today that its Board of Directors has approved the terms of the issuance of transferable rights ("Rights") to the holders of the Fund's common stock (par value $0.001 per share), as of the record date, June 18, 2026 (the "Record Date"). Holders of these Rights will be entitled to subscribe for additional shares of common stock (the "Offer").

PRNewsWire • Jun 8, 2026